ProShare Advisors’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $832K | Sell |
14,163
-1,596
| -10% | -$66.9K | ﹤0.01% | 853 |
|
|
2026
Q1 | $508K | Sell |
15,759
-2,984
| -16% | -$110K | ﹤0.01% | 1053 |
|
|
2025
Q4 | $789K | Buy |
18,743
+1,168
| +7% | +$47.1K | ﹤0.01% | 906 |
|
|
2025
Q3 | $603K | Sell |
17,575
-1,422
| -7% | -$40.8K | ﹤0.01% | 1020 |
|
|
2025
Q2 | $513K | Sell |
18,997
-1,384
| -7% | -$40.1K | ﹤0.01% | 1115 |
|
|
2025
Q1 | $604K | Sell |
20,381
-4,930
| -19% | -$188K | ﹤0.01% | 996 |
|
|
2024
Q4 | $1M | Buy |
25,311
+6,251
| +33% | +$237K | ﹤0.01% | 918 |
|
|
2024
Q3 | $649K | Buy |
19,060
+4,590
| +32% | +$129K | ﹤0.01% | 986 |
|
|
2024
Q2 | $314K | Sell |
14,470
-3,872
| -21% | -$81.4K | ﹤0.01% | 1265 |
|
|
2024
Q1 | $406K | Buy |
18,342
+1,625
| +10% | +$39.6K | ﹤0.01% | 1215 |
|
|
2023
Q4 | $460K | Buy |
16,717
+2,505
| +18% | +$60.5K | ﹤0.01% | 1090 |
|
|
2023
Q3 | $317K | Buy |
14,212
+58
| +0.4% | +$1.49K | ﹤0.01% | 1175 |
|
|
2023
Q2 | $361K | Sell |
14,154
-49
| -0.3% | -$1.19K | ﹤0.01% | 1155 |
|
|
2023
Q1 | $317K | Sell |
14,203
-952
| -6% | -$23K | ﹤0.01% | 1185 |
|
|
2022
Q4 | $360K | Buy |
15,155
+1,234
| +9% | +$28.7K | ﹤0.01% | 1128 |
|
|
2022
Q3 | $231K | Buy |
13,921
+307
| +2% | +$6.91K | ﹤0.01% | 1311 |
|
|
2022
Q2 | $270K | Sell |
13,614
-6,407
| -32% | -$129K | ﹤0.01% | 1270 |
|
|
2022
Q1 | $552K | Sell |
20,021
-4,710
| -19% | -$135K | ﹤0.01% | 1223 |
|
|
2021
Q4 | $1.02M | Buy |
24,731
+945
| +4% | +$41.7K | ﹤0.01% | 1009 |
|
|
2021
Q3 | $1.1M | Sell |
23,786
-5,802
| -20% | -$253K | ﹤0.01% | 873 |
|
|
2021
Q2 | $1.18M | Buy |
29,588
+2,613
| +10% | +$112K | ﹤0.01% | 939 |
|
|
2021
Q1 | $1.45M | Buy |
26,975
+5,350
| +25% | +$308K | ﹤0.01% | 810 |
|
|
2020
Q4 | $1.06M | Buy |
21,625
+5,485
| +34% | +$254K | ﹤0.01% | 853 |
|
|
2020
Q3 | $524K | Buy |
16,140
+1,347
| +9% | +$42.8K | ﹤0.01% | 924 |
|
|
2020
Q2 | $383K | Buy |
14,793
+5,307
| +56% | +$132K | ﹤0.01% | 1082 |
|
|
2020
Q1 | $231K | Sell |
9,486
-7,471
| -44% | -$188K | ﹤0.01% | 960 |
|
|
2019
Q4 | $473K | Sell |
16,957
-1,533
| -8% | -$39.7K | ﹤0.01% | 1092 |
|
|
2019
Q3 | $444K | Buy |
18,490
+1,736
| +10% | +$46.2K | ﹤0.01% | 1020 |
|
|
2019
Q2 | $478K | Sell |
16,754
-286
| -2% | -$7.14K | ﹤0.01% | 1033 |
|
|
2019
Q1 | $426K | Buy |
17,040
+291
| +2% | +$5.56K | ﹤0.01% | 1082 |
|
|
2018
Q4 | $211K | Sell |
16,749
-2,797
| -14% | -$33.1K | ﹤0.01% | 1349 |
|
|
2018
Q3 | $187K | Buy |
19,546
+1,927
| +11% | +$21.3K | ﹤0.01% | 1612 |
|
|
2018
Q2 | $165K | Sell |
17,619
-1,264
| -7% | -$8.89K | ﹤0.01% | 1650 |
|
|
2018
Q1 | $105K | Sell |
18,883
-2,971
| -14% | -$18.4K | ﹤0.01% | 1634 |
|
|
2017
Q4 | $143K | Buy |
+21,854
| New | +$162K | ﹤0.01% | 1699 |
|
Other funds holding VCYT
AIM
ProShare Advisors's VCYT Position: Q2 2026 in Review
ProShare Advisors reduced its Veracyte (VCYT) stake by 10% in Q2 2026, selling an estimated $66.9K and leaving 14,163 shares worth $832K. The position accounts for ﹤0.01% of the portfolio, ranked #853.
ProShare Advisors first reported a position in VCYT in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.45M in Q1 2021. 371 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.
- ProShare Advisors held 14,163 shares of Veracyte worth $832K as of Q2 2026.
- ProShare Advisors sold 1,596 Veracyte shares in Q2 2026, an estimated $66.9K.
- Veracyte made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #853 holding.
- ProShare Advisors first reported a position in Veracyte in Q4 2017 and has held it in 35 quarters since.
- ProShare Advisors's Veracyte position peaked at $1.45M in Q1 2021.
- 371 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.